Clinical trials: Recurrent Islet Cell Carcinoma
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00227617
- Testing
- bevacizumab, 5-fluorouracil, leucovorin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Gastrinoma, Glucagonoma
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
This randomized phase II trial studies how well everolimus works in treating patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Liver Metastases
- Trial name
- NCT02031536
- Testing
- everolimus
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Gastrinoma, Glucagonoma
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT02259725
- Testing
- regorafenib, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Colorectal Cancer, Islet Cell Tumor
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer
- Trial name
- NCT00019786
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Islet Cell Tumor, Pancreatic Cancer
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic…
- Conditions
- Islet Cell Tumor, Pancreatic Cancer, Pancreatic Disease, Acute Pancreatitis
- Trial name
- NCT00830557
- Testing
- medical chart review, survey administration, biospecimen collection
- Where
- 3 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- Mayo Clinic
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602082
- Testing
- capecitabine, cisplatin, streptozocin
- Where
- 17 sites in United Kingdom
- Volunteers
- 84 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Malignant Head and Neck Neoplasm, Malignant Neoplasm
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and…
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix
- Trial name
- NCT01365169
- Testing
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
This phase I/II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how well they work in treating patients with advanced pancreatic neuroendocrine tumors (PNET)…
- Conditions
- Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Carcinoma, Pancreatic G-cell Carcinoma
- Trial name
- NCT01465659
- Testing
- temozolomide, pazopanib hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Northwestern University
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system…
- Conditions
- Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
- Trial name
- NCT03074513
- Testing
- Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- M.D. Anderson Cancer Center
Gastrinoma, Glucagonoma
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
This phase II trial studies how well dovitinib lactate works in treating patients with pancreatic neuroendocrine tumors. Dovitinib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor
- Trial name
- NCT02108782
- Testing
- dovitinib lactate, pharmacological study, laboratory biomarker analysis
- Sponsor
- Academic and Community Cancer Research United
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Islet Cell Tumor
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
- Trial name
- NCT00466856
- Testing
- octreotide acetate, yttrium Y 90 resin microspheres
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer.
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma
- Trial name
- NCT01204476
- Testing
- Cixutumumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Gastrinoma, Glucagonoma
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma
- Trial name
- NCT01824875
- Testing
- temozolomide, capecitabine
- Where
- 323 sites in United States
- Volunteers
- 144 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma
- Trial name
- NCT00049023
- Testing
- 90Y-DOTA-tyr3-OCTREOTIDE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- O'Dorisio, M S